In October 2015, Medistim entered into an exclusive License and OEM agreement with em-tec GmbH, to market and sell em-tec’s transit time flow measurement (TTFM) technology.
(Oslo, November 10th 2016), Medistim ASA (OSE: MEDI), a medtech company that develops and distributes surgical guidance and quality assessment devices, launches the Medistim SonoQ™.
In October 2015, Medistim entered into an exclusive License and OEM agreement with em-tec GmbH, to market and sell em-tec’s transit time flow measurement (TTFM) technology. This flowmeter is a basic solution that suits price sensitive market segments and fills a gap within Medistim’s product portfolio. The first Medistim labeled device based on this technology is now being launched in selected markets.
The SonoQ is a device that accurately measures blood flow intraoperatively. The features have been adapted to address the specific needs of this market segment. The system has a small footprint, and can easily be shared between departments and operating rooms, supporting high productivity in the hospital.
One of the most important target markets for the SonoQ is India, a market with about 150,000 coronary artery bypass procedures per year, which is very low compared to the population size of 1.3 billion, and therefore expected to grow. In collaboration with our local distributor, Medistim is launching the new product at the International Coronary Congress in New Delhi, India, on November 11-13. This meeting is dedicated to state of the art surgical coronary revascularization, and the program highlights the necessity of surgical guidance and quality assessment based on intraoperative ultrasound and TTFM.
“While Medistim is the market leader with our own high-end products for surgical guidance and blood flow measurement in cardiac-, vascular and transplant surgery, we have been lacking a basic TTFM system to reach some emerging market segments,” says Medistim President and CEO, Kari E. Krogstad. “India is a market where we have been present for years and achieved occasional sales of our advanced products VeriQ™ and MiraQ™, but we believe a lower price-point solution is necessary to accelerate adoption both in the private hospital chains and the public health system. We look forward to continue our collaboration with Indian surgeons and support their work to achieve the best possible surgical outcomes.”
Medistim is a medtech company that develops and distributes ultrasound based surgical guidance and quality assessment devices. With headquarters in Oslo, Norway, Medistim was established in 1984, and has a track record of profitable growth over the past >10 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Denmark and Norway, in addition to about 50 distributors in Europe, Asia, Middle East, Africa and South America.
For more information, visit the Medistim home page: www.medistim.com
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).